Wall Street analysts forecast that Tandem Diabetes Care Inc (NASDAQ:TNDM) will post earnings of ($0.44) per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Tandem Diabetes Care’s earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.38). Tandem Diabetes Care posted earnings of ($0.97) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 54.6%. The business is expected to issue its next quarterly earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.40) to ($1.46). For the next financial year, analysts expect that the business will report earnings of ($1.21) per share, with EPS estimates ranging from ($2.18) to ($0.76). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.04. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $21.74 million. During the same quarter in the previous year, the company posted ($0.60) EPS. The company’s quarterly revenue was down 7.4% on a year-over-year basis.

TNDM has been the subject of a number of research reports. B. Riley restated a “neutral” rating and set a $1.50 target price on shares of Tandem Diabetes Care in a research report on Wednesday, May 3rd. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $4.71.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/0-44-earnings-per-share-expected-for-tandem-diabetes-care-inc-tndm-this-quarter/1496374.html.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded down 2.9934% during midday trading on Wednesday, reaching $0.7324. The company’s stock had a trading volume of 4,430,632 shares. The firm’s market capitalization is $36.79 million. Tandem Diabetes Care has a 12-month low of $0.39 and a 12-month high of $8.81. The stock has a 50-day moving average of $0.61 and a 200 day moving average of $1.22.

Several hedge funds and other institutional investors have recently modified their holdings of TNDM. Wrapmanager Inc. increased its position in shares of Tandem Diabetes Care by 59.2% in the first quarter. Wrapmanager Inc. now owns 96,405 shares of the medical device company’s stock worth $116,000 after buying an additional 35,866 shares during the period. Iguana Healthcare Management LLC increased its position in shares of Tandem Diabetes Care by 33.3% in the first quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after buying an additional 25,000 shares during the period. OLD National Bancorp IN increased its position in shares of Tandem Diabetes Care by 31.0% in the first quarter. OLD National Bancorp IN now owns 119,779 shares of the medical device company’s stock worth $144,000 after buying an additional 28,320 shares during the period. Monashee Investment Management LLC purchased a new position in shares of Tandem Diabetes Care during the first quarter worth $180,000. Finally, Group One Trading L.P. purchased a new position in shares of Tandem Diabetes Care during the first quarter worth $185,000. Institutional investors and hedge funds own 45.22% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.